ClariVest Asset Management LLC reduced its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 51.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,561 shares of the biopharmaceutical company’s stock after selling 43,152 shares during the quarter. ClariVest Asset Management LLC owned 0.05% of FibroGen worth $2,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in FGEN. SG Americas Securities LLC increased its position in FibroGen by 107.6% during the third quarter. SG Americas Securities LLC now owns 14,006 shares of the biopharmaceutical company’s stock valued at $754,000 after acquiring an additional 7,259 shares during the last quarter. Bank of New York Mellon Corp increased its position in FibroGen by 26.3% during the third quarter. Bank of New York Mellon Corp now owns 369,599 shares of the biopharmaceutical company’s stock valued at $19,884,000 after acquiring an additional 76,963 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in FibroGen during the third quarter valued at $299,000. Rhumbline Advisers increased its position in FibroGen by 19.6% during the third quarter. Rhumbline Advisers now owns 81,521 shares of the biopharmaceutical company’s stock valued at $4,386,000 after acquiring an additional 13,354 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in FibroGen by 5.7% during the third quarter. New York State Common Retirement Fund now owns 71,589 shares of the biopharmaceutical company’s stock valued at $3,851,000 after acquiring an additional 3,889 shares during the last quarter. 50.82% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider K Peony Yu sold 15,000 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $60.00, for a total transaction of $900,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jorma Routti sold 12,000 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $47.36, for a total value of $568,320.00. Following the sale, the director now owns 133,840 shares of the company’s stock, valued at approximately $6,338,662.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 457,518 shares of company stock valued at $23,754,691. Company insiders own 14.90% of the company’s stock.

FGEN has been the subject of a number of research reports. Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Mizuho initiated coverage on FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Finally, Citigroup Inc. upped their price objective on FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $65.67.

Shares of FibroGen, Inc (NASDAQ:FGEN) traded up $0.67 on Tuesday, reaching $47.55. The company’s stock had a trading volume of 385,000 shares, compared to its average volume of 628,263. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen, Inc has a fifty-two week low of $19.25 and a fifty-two week high of $60.15.

TRADEMARK VIOLATION NOTICE: “FibroGen, Inc (FGEN) Shares Sold by ClariVest Asset Management LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/21/fibrogen-inc-fgen-shares-sold-by-clarivest-asset-management-llc.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.